{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:35:53Z","timestamp":1778254553564,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.amjmed.2005.09.035","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T14:00:46Z","timestamp":1137679246000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"S2","title":["Vasomotor symptom relief versus unwanted effects: role of estrogen dosage"],"prefix":"10.1016","volume":"118","author":[{"given":"Bruce","family":"Ettinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.09.035_bib1","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms\u2014Prescribing Information for Health Care Providers and Patient Labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; February 2004. Available at: http:\/\/www.fda.gov\/cder\/guidance\/5670dft.doc. Accessed February 15, 2005."},{"issue":"suppl","key":"10.1016\/j.amjmed.2005.09.035_bib2","first-page":"1S","article-title":"Executive summary","volume":"104","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use of postmenopausal hormone therapy","volume":"291","author":"Hersh","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.09.035_bib4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/01.AOG.0000143826.38439.af","article-title":"Hormone therapy prescribing patterns in the United States","volume":"104","author":"Buist","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib5","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms\u2014Recommendations for Clinical Evaluation[draft guidance]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; January 2003. Available at: http:\/\/www.fda.gov\/cder\/guidance\/5412dft.doc. Accessed February 15, 2005."},{"key":"10.1016\/j.amjmed.2005.09.035_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0029-7844(96)00272-4","article-title":"Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms","volume":"88","author":"Speroff","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9378(99)70438-2","article-title":"Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim\u00ae) compared with placebo on vasomotor symptoms in highly symptomatic patients","volume":"181","author":"Utian","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00044011-200020040-00001","article-title":"Randomized, controlled comparison of transdermal estradiol with oral conjugated estrogens for the relief of hot flushes","volume":"20","author":"Parsey","year":"2000","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.amjmed.2005.09.035_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00042192-200011000-00003","article-title":"The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femHRT\u00ae) on the frequency and intensity of vasomotor symptoms","volume":"7","author":"Speroff","year":"2000","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib10","first-page":"726","article-title":"Initial 17\u03b2-estradiol dose for treating vasomotor symptoms","volume":"95","author":"Notelovitz","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00042192-200007050-00005","article-title":"Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17\u03b2-estradiol","volume":"7","author":"Notelovitz","year":"2000","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogen and medroxyprogesterone acetate","volume":"75","author":"Utian","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.amjmed.2005.09.035_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.AOG.0000109428.87940.31","article-title":"Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens","volume":"103","author":"Utian","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib14","first-page":"130","article-title":"Low-dose unopposed estrogens","volume":"4","author":"Trabal","year":"1997","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0015-0282(01)01792-7","article-title":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding","volume":"75","author":"Archer","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.amjmed.2005.09.035_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00042192-200209000-00007","article-title":"Effectiveness of Alora\u00ae estradiol matrix delivery system in improving lumbar bone mineral density in healthy, postmenopausal women","volume":"9","author":"Notelovitz","year":"2002","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00042192-199906040-00003","article-title":"Effect of age on reasons for initiation and discontinuation of hormone replacement therapy","volume":"6","author":"Ettinger","year":"1999","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0015-0282(01)01828-3","article-title":"Endometrial effects of lower doses of conjugated estrogens and medroxyprogesterone acetate","volume":"76","author":"Pickar","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.amjmed.2005.09.035_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00042192-200203000-00009","article-title":"Low dose transdermal estradiol\/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women","volume":"9","author":"Brynhildsen","year":"2002","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.09.035_bib20","first-page":"693","article-title":"Cyclic hormone replacement therapy using quarterly progestin","volume":"83","author":"Ettinger","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib21","first-page":"205","article-title":"Low-dosage esterified estrogen opposed by progestin at 6-month intervals","volume":"98","author":"Ettinger","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9378(97)80022-1","article-title":"Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women","volume":"176","author":"Ettinger","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.09.035_bib23","unstructured":"The 2004 Gallup Study of Women\u2019s Experiences with Hormone Replacement Therapy. Princeton, NJ: Multi-sponsor Surveys, Inc. Catalog No. 257. Available at: http:\/\/www.multi-sponsorsurveys.com. Accessed February 17, 2005."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305008910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305008910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:41:34Z","timestamp":1757580094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305008910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0002934305008910"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.035","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasomotor symptom relief versus unwanted effects: role of estrogen dosage","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}